[CAS NO. 2070015-26-6] SRT3025 HCl
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [2070015-26-6]
Store
Catalog
SLK-S8481
Brand
Selleck
CAS
2070015-26-6
DESCRIPTION [2070015-26-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 606.2 |
| Molecular Formula | C31H31N5O2S2.HCl |
| SMILES | O=C(C1=C(CCCOC)SC(C2=CC=CC=C2)=N1)NC3=CC=CC=C3C4=NC5=CC(CN6CCCC6)=CN=C5S4.[H]Cl |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6496 mL | 8.2481 mL | 16.4962 mL |
| 5 mM | 0.3299 mL | 1.6496 mL | 3.2992 mL |
| 10 mM | 0.1650 mL | 0.8248 mL | 1.6496 mL |
| 50 mM | 0.0330 mL | 0.1650 mL | 0.3299 mL |
Description
SRT3025 is an orally available small molecule activator of the enzyme.
Targets
| SIRT1 [1] (Cell-free assay) |
In vitro
SRT3025 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway. SRT3025 acts faster than oxymetholone to improve hematopoiesis. It does not work by direct activation of Sirt1 in hematopoietic cells. SRT3025 might suppress p21 transcription through the down-regulation of Egr1. SRT3025 is found to activate wild-type Sirt1 protein but failed to activate the E230K mutant, an activation-resistant Sirt1 protein (due to a mutation at position 230).
In vivo
SRT3025 treatment also inhibits tumor growth in Panc-1 xenografts, even though it is not as effective in inhibiting the viability of Panc-1 cells in culture. SRT3025 is well tolerated in mice and has the potential to be used in several diseases. SRT3025 administration expands HSPCs and boosts blood counts while long term SRT3025 administration does not permanently increase or decrease HSC repopulating potential. SRT3025 reduces plasma cholesterol, inflammation, and atherosclerosis in Apoe−/− mice, and it increases hepatic Ldlr expression and Pcsk9 accumulation.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.